lysine octadecyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: lysine octadecyl ester
• 英文别名: octadecyl lysinate；Octadecyl 2,6-diaminohexanoate
• 化学式: C₂₄H₅₀N₂O₂
• 分子量: 398.673
• InChiKey: QTPSKWKTARMYJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  28
• 可旋转键数：
  23
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  78.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Optically fluorescent nanoparticles
  申请人：Schering AG

  公开号：EP1760467A1

  公开（公告）日：2007-03-07

  The present invention refers to nanoparticles having optically fluorescent activity. In more detail, the invention refers to a nanoparticle matrix comprising a co-aggregate of at least one charged polyelectrolyte and at least one oppositely charged active agent, wherein the active agent is a hydrophilic optically fluorescent agent, and the invention further refers to a nanoparticle comprising said nanoparticle matrix. Optionally, the nanoparticle is surface modified. The invention also refers to a method for preparing said nanoparticle, and to a method of surface modification. Furthermore, the invention refers to uses of said nanoparticle in vitro and in vivo, and to methods for in vitro and in vivo diagnosis.

  本发明涉及具有光学荧光活性的纳米颗粒。更具体地说，本发明涉及一种纳米颗粒基质，其包括至少一种带电聚电解质和至少一种相反带电的活性剂的共聚物，其中活性剂是亲水性光学荧光剂，本发明还涉及包括该纳米颗粒基质的纳米颗粒。可选地，纳米颗粒可以表面修饰。本发明还涉及制备该纳米颗粒的方法和表面修饰的方法。此外，本发明还涉及在体外和体内使用该纳米颗粒的用途，以及体外和体内诊断的方法。
• Lysine esters used as absorption enhancing agents
  申请人：Merck & Co., Inc.

  公开号：EP0162747A1

  公开（公告）日：1985-11-27

  Novel lysine esters used as absorption enhancing agents for gastrointestinally and rectally administered drugs. Also provided are processes for preparation of said lysine ester coupounds as well as pharmaceutical formulations and methods for their use as absorption enhancing agents.

  新型赖氨酸酯可用作胃肠道和直肠给药的促进吸收剂。此外，还提供了上述赖氨酸酯偶联物的制备工艺以及用作吸收促进剂的药物制剂和方法。
• Stabilization of amorphous drugs using sponge-like carrier matrices
  申请人：Capsulution Nanoscience AG

  公开号：EP2135601A1

  公开（公告）日：2009-12-23

  The present invention relates to drug formulations for the stabilization of amorphous forms of drugs. In particular the present invention relates to pharmaceutical compositions comprising sponge-like carrier matrices, particularly polyelectrolyte complexes or porous particles. The invention also relates to methods for the production of such pharmaceutical compositions.

  本发明涉及用于稳定无定形药物的药物制剂。本发明尤其涉及包含海绵状载体基质，特别是聚电解质复合物或多孔颗粒的药物组合物。本发明还涉及生产此类药物组合物的方法。
• Improved nanoparticulate compositions of poorly soluble compounds
  申请人：Capsulution Nanoscience AG

  公开号：EP2172193A1

  公开（公告）日：2010-04-07

  The present invention relates to a method for the production of a nanoparticulate pharmaceutical composition. The method comprises the steps of a) suspending in water a poorly soluble active ingredient without the presence of a detergent, b) mechanically treating said suspension to obtain particles comprising the active ingredient with an effective average size of less than about 5000 nm, c) contacting said active ingredient or suspension with a first polyelectrolyte during and/or before mechanically treating, d) optionally contacting said suspension with a one or more second or further polyelectrolytes during, before and/or after mechanically treating, e) optionally drying said suspension. The invention also pertains to the pharmaceutical compositions obtained by the method of the invention.

  本发明涉及一种生产纳米颗粒药物组合物的方法。该方法包括以下步骤：a) 将溶解性差的活性成分悬浮于水中，且不含洗涤剂；b) 对所述悬浮液进行机械处理，以获得包含有效平均粒径小于约 5000 nm 的活性成分的颗粒；c) 在机械处理过程中和/或之前，将所述活性成分或悬浮液与第一种聚电解质接触；d) 在机械处理过程中、之前和/或之后，选择性地将所述悬浮液与一种或多种第二种或更多的聚电解质接触；e) 选择性地干燥所述悬浮液。本发明还涉及通过本发明方法获得的药物组合物。
• Pharmakologische Zubereitung, enthaltend Polyelektrolytkomplexe in mikropartikulärer Form und mindestens einen Wirkstoff
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0454044B1

  公开（公告）日：1995-12-06